MX2017012982A - Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. - Google Patents
Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.Info
- Publication number
- MX2017012982A MX2017012982A MX2017012982A MX2017012982A MX2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A MX 2017012982 A MX2017012982 A MX 2017012982A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- compositions
- methods
- immunomodulatory
- monocytes
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000001616 monocyte Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación provee composiciones farmacóuticas que comprenden ácidos nucleicos capaces de hacer blanco en la expresión de IGF-1R en las cólulas M2; la presente divulgación también provee métodos para la reducción selectiva de cólulas M2 haciendo blanco en la expresión de IGF-1R en estas cólulas; la presente divulgación provee, además, métodos para el tratamiento del cáncer y mejoramiento terapóutico haciendo blanco en la expresión de IGF-1R en cólulas M2 en los pacientes; la composición farmacóutica de la presente invención es eficaz cuando se le administra sistómicamente a los sujetos que la necesitan; la facilidad de administración de la composición farmacóutica facilita el tratamiento y mejora el cumplimiento del paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562145758P | 2015-04-10 | 2015-04-10 | |
PCT/US2016/026970 WO2016164916A1 (en) | 2015-04-10 | 2016-04-11 | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017012982A true MX2017012982A (es) | 2018-07-06 |
Family
ID=57072956
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017012982A MX2017012982A (es) | 2015-04-10 | 2016-04-11 | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. |
MX2021012272A MX2021012272A (es) | 2015-04-10 | 2017-10-09 | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012272A MX2021012272A (es) | 2015-04-10 | 2017-10-09 | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. |
Country Status (8)
Country | Link |
---|---|
US (5) | US10206942B2 (es) |
EP (1) | EP3280806A4 (es) |
JP (3) | JP6957035B2 (es) |
CN (1) | CN108260357A (es) |
AU (2) | AU2016246134B2 (es) |
CA (1) | CA2982205A1 (es) |
MX (2) | MX2017012982A (es) |
WO (1) | WO2016164916A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108260357A (zh) | 2015-04-10 | 2018-07-06 | 托马斯杰弗逊大学 | 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物 |
EP3585815A4 (en) * | 2017-02-24 | 2021-03-17 | Thomas Jefferson University | METHODS AND COMPOSITIONS FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS |
NZ756820A (en) | 2017-03-09 | 2022-08-26 | Univ Jefferson | Methods and compositions for treating cancers using antisense |
CA3060090A1 (en) * | 2017-04-19 | 2018-10-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for igf-1r inhibition |
AU2018255353B2 (en) * | 2017-04-19 | 2023-11-16 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for IGF-1R inhibition |
WO2019014511A2 (en) * | 2017-07-14 | 2019-01-17 | Minzhen Xu | METHOD FOR INDUCING AN IMMUNE RESPONSE DOMINATED BY M1 AND PHARMACEUTICAL COMPOSITIONS |
GB201714330D0 (en) * | 2017-09-06 | 2017-10-18 | Järver Peter | Oligonucleotides |
BR112020015028A2 (pt) * | 2018-01-24 | 2020-12-29 | Thomas Jefferson University | Câmara de biodifusão |
US20220000916A1 (en) * | 2018-11-02 | 2022-01-06 | Thomas Jefferson University | Methods and compositions for treating breast cancer using antisense |
WO2020092682A1 (en) * | 2018-11-02 | 2020-05-07 | Thomas Jefferson University | Methods and compositions for treating hepatocellular carcinoma using antisense |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK114394B (da) | 1963-06-17 | 1969-06-23 | O Hoyer | Fremgangsmåde ved emballering af aflange formlegemer, navnlig ispinde, samt maskine til udøvelse af fremgangsmåden. |
US3331526A (en) | 1964-07-20 | 1967-07-18 | Levenson Leonard Lionel | Ultrahigh vacuum seal |
EP0750516A4 (en) | 1993-03-26 | 1998-07-01 | Univ Jefferson | METHOD FOR INHIBITING CELL PROLIFERATION AND TRIGGERING CELL DIFFERENTIATION USING TYPE 1 GROWTH FACTOR RECEPTOR OLIGONUCLEOTIDES |
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
US5714170A (en) * | 1994-11-16 | 1998-02-03 | Thomas Jefferson University | Method of inducing resistance to tumor growth |
US6541036B1 (en) | 1997-05-29 | 2003-04-01 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR) |
CA2339858A1 (en) * | 1998-08-13 | 2000-02-24 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |
US6144553A (en) | 1998-09-09 | 2000-11-07 | Sun Microsystems, Inc. | Refrigeration cooled disk storage assembly |
US7846906B2 (en) | 2003-02-28 | 2010-12-07 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
CA2447400A1 (en) | 2003-09-12 | 2005-03-12 | The Hospital For Sick Children | Brain tumor stem cells |
CN102898426B (zh) * | 2012-11-15 | 2015-04-22 | 江苏先声药业有限公司 | 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物 |
CN108260357A (zh) | 2015-04-10 | 2018-07-06 | 托马斯杰弗逊大学 | 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物 |
NZ756820A (en) | 2017-03-09 | 2022-08-26 | Univ Jefferson | Methods and compositions for treating cancers using antisense |
-
2016
- 2016-04-11 CN CN201680033742.1A patent/CN108260357A/zh active Pending
- 2016-04-11 MX MX2017012982A patent/MX2017012982A/es unknown
- 2016-04-11 AU AU2016246134A patent/AU2016246134B2/en active Active
- 2016-04-11 US US15/095,877 patent/US10206942B2/en active Active
- 2016-04-11 EP EP16777497.5A patent/EP3280806A4/en active Pending
- 2016-04-11 CA CA2982205A patent/CA2982205A1/en active Pending
- 2016-04-11 JP JP2018504082A patent/JP6957035B2/ja active Active
- 2016-04-11 WO PCT/US2016/026970 patent/WO2016164916A1/en active Application Filing
-
2017
- 2017-10-09 MX MX2021012272A patent/MX2021012272A/es unknown
-
2018
- 2018-01-10 US US15/867,000 patent/US10543226B2/en active Active
- 2018-05-18 US US15/983,796 patent/US10265339B2/en active Active
-
2019
- 2019-12-12 US US16/711,470 patent/US11077133B2/en active Active
-
2021
- 2021-07-01 US US17/365,209 patent/US20220072025A1/en active Pending
- 2021-09-29 JP JP2021158687A patent/JP7428397B2/ja active Active
-
2022
- 2022-07-21 AU AU2022206776A patent/AU2022206776A1/en active Pending
-
2024
- 2024-01-18 JP JP2024006202A patent/JP2024028529A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016246134B2 (en) | 2022-04-21 |
CN108260357A (zh) | 2018-07-06 |
US20180235996A1 (en) | 2018-08-23 |
AU2022206776A1 (en) | 2022-09-15 |
WO2016164916A1 (en) | 2016-10-13 |
JP2021193143A (ja) | 2021-12-23 |
US10206942B2 (en) | 2019-02-19 |
CA2982205A1 (en) | 2016-10-13 |
US20200197435A1 (en) | 2020-06-25 |
US20180271894A1 (en) | 2018-09-27 |
MX2021012272A (es) | 2021-11-12 |
US11077133B2 (en) | 2021-08-03 |
EP3280806A4 (en) | 2018-12-05 |
US20170056430A1 (en) | 2017-03-02 |
US10265339B2 (en) | 2019-04-23 |
JP7428397B2 (ja) | 2024-02-06 |
JP2018515598A (ja) | 2018-06-14 |
JP6957035B2 (ja) | 2021-11-02 |
AU2016246134A1 (en) | 2017-11-02 |
US10543226B2 (en) | 2020-01-28 |
US20220072025A1 (en) | 2022-03-10 |
JP2024028529A (ja) | 2024-03-04 |
EP3280806A1 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012272A (es) | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
MY188139A (en) | Sodium channel modulators for the treatment of pain | |
MX2022015748A (es) | Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer. | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
WO2016025635A3 (en) | Combination therapy for treating cancer | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
WO2016043874A3 (en) | Combination therapy for treating cancer | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2018000262A (es) | Usos terapeuticos de formulaciones de berberina. | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. |